1. Brooke JS.
Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012; 25:2–41. PMID:
22232370.
2. Hu LF, Gao LP, Ye Y, Chen X, Zhou XT, Yang HF, et al. Susceptibility of
Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations. J Chemother. 2014; 26:282–286. PMID:
24588423.
3. Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, Shi W, et al.
Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of
sul and
dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents. 2011; 37:230–234. PMID:
21296557.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-third informational supplement, M100-S23. Wayne, PA: CLSI;2013.
5. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. Global emergence of trimethoprim/sulfamethoxazole resistance in
Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis. 2007; 13:559–565. PMID:
17553270.
6. Trinh Q, Zhu P, Shi H, Xu W, Hao J, Luo Y, et al. A-T linker adapter polymerase chain reaction for determining flanking sequences by rescuing inverse PCR or thermal asymmetric interlaced PCR products. Anal Biochem. 2014; 466:24–26. PMID:
25086366.
7. Nazik H, Ongen B, Erturan Z, Salcioğlu M. Genotype and antibiotic susceptibility patterns of
Pseudonas aeruginosa and
Stenotrophomonas maltophilia isolated from cystic fibrosis patients. Jpn J Infect Dis. 2007; 60:82–86. PMID:
17515637.